Cargando…

Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis

Since the first model of experimental autoimmune encephalomyelitis (EAE) was introduced almost a century ago, there has been an ongoing scientific debate about the risks and benefits of using EAE as a model of multiple sclerosis (MS). While there are notable limitations of translating EAE studies di...

Descripción completa

Detalles Bibliográficos
Autores principales: Melamed, Esther, Palmer, Jamie L., Fonken, Cara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672668/
https://www.ncbi.nlm.nih.gov/pubmed/36407764
http://dx.doi.org/10.3389/fnmol.2022.1019877
_version_ 1784832788540686336
author Melamed, Esther
Palmer, Jamie L.
Fonken, Cara
author_facet Melamed, Esther
Palmer, Jamie L.
Fonken, Cara
author_sort Melamed, Esther
collection PubMed
description Since the first model of experimental autoimmune encephalomyelitis (EAE) was introduced almost a century ago, there has been an ongoing scientific debate about the risks and benefits of using EAE as a model of multiple sclerosis (MS). While there are notable limitations of translating EAE studies directly to human patients, EAE continues to be the most widely used model of MS, and EAE studies have contributed to multiple key breakthroughs in our understanding of MS pathogenesis and discovery of MS therapeutics. In addition, insights from EAE have led to a better understanding of modifiable environmental factors that can influence MS initiation and progression. In this review, we discuss how MS patient and EAE studies compare in our learning about the role of gut microbiome, diet, alcohol, probiotics, antibiotics, and fecal microbiome transplant in neuroinflammation. Ultimately, the combination of rigorous EAE animal studies, novel bioinformatic approaches, use of human cell lines, and implementation of well-powered, age- and sex-matched randomized controlled MS patient trials will be essential for improving MS patient outcomes and developing novel MS therapeutics to prevent and revert MS disease progression.
format Online
Article
Text
id pubmed-9672668
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96726682022-11-19 Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis Melamed, Esther Palmer, Jamie L. Fonken, Cara Front Mol Neurosci Molecular Neuroscience Since the first model of experimental autoimmune encephalomyelitis (EAE) was introduced almost a century ago, there has been an ongoing scientific debate about the risks and benefits of using EAE as a model of multiple sclerosis (MS). While there are notable limitations of translating EAE studies directly to human patients, EAE continues to be the most widely used model of MS, and EAE studies have contributed to multiple key breakthroughs in our understanding of MS pathogenesis and discovery of MS therapeutics. In addition, insights from EAE have led to a better understanding of modifiable environmental factors that can influence MS initiation and progression. In this review, we discuss how MS patient and EAE studies compare in our learning about the role of gut microbiome, diet, alcohol, probiotics, antibiotics, and fecal microbiome transplant in neuroinflammation. Ultimately, the combination of rigorous EAE animal studies, novel bioinformatic approaches, use of human cell lines, and implementation of well-powered, age- and sex-matched randomized controlled MS patient trials will be essential for improving MS patient outcomes and developing novel MS therapeutics to prevent and revert MS disease progression. Frontiers Media S.A. 2022-11-04 /pmc/articles/PMC9672668/ /pubmed/36407764 http://dx.doi.org/10.3389/fnmol.2022.1019877 Text en Copyright © 2022 Melamed, Palmer and Fonken. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Neuroscience
Melamed, Esther
Palmer, Jamie L.
Fonken, Cara
Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
title Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
title_full Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
title_fullStr Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
title_full_unstemmed Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
title_short Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
title_sort advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
topic Molecular Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672668/
https://www.ncbi.nlm.nih.gov/pubmed/36407764
http://dx.doi.org/10.3389/fnmol.2022.1019877
work_keys_str_mv AT melamedesther advantagesandlimitationsofexperimentalautoimmuneencephalomyelitisinbreakingdowntheroleofthegutmicrobiomeinmultiplesclerosis
AT palmerjamiel advantagesandlimitationsofexperimentalautoimmuneencephalomyelitisinbreakingdowntheroleofthegutmicrobiomeinmultiplesclerosis
AT fonkencara advantagesandlimitationsofexperimentalautoimmuneencephalomyelitisinbreakingdowntheroleofthegutmicrobiomeinmultiplesclerosis